Document:

exv10w52

 

Exhibit 10.52

LYNX THERAPEUTICS, INC.

EMPLOYEE AGREEMENT

for

Mary L. Schramke, Ph.D., MBA

     This Employment Agreement (“Agreement”) by and between Mary L. Schramke,
Ph.D., MBA (“Ms. Schramke”) and LYNX THERAPEUTICS, INC., a Delaware corporation
(the “Company”), is entered into and is effective as of January 29, 2003 (the
“Effective Date”).

     WHEREAS, the Company desires to employ Ms. Schramke to provide personal
services to the Company, and wishes to provide Ms. Schramke with certain
compensation and benefits in return for her services; and

     WHEREAS, Ms. Schramke wishes to be employed by the Company and provide
personal services to the Company in return for certain compensation and
benefits;

     NOW, THEREFORE, in consideration of the mutual promises and covenants
contained herein, it is hereby agreed by and between the parties hereto as
follows:

     1. EMPLOYMENT BY THE COMPANY.

          1.1 Subject to the terms set forth herein, the Company agrees to employ
Ms. Schramke in the position of Sr. Director, Business Development, reporting
to the Vice President of Business Development, and Ms. Schramke hereby accepts
such employment effective as of January 29, 2003. During the term of her
employment with the Company, Ms. Schramke will devote her best efforts and
substantially all of her business time and attention (except for vacation
periods permitted by the Company’s general employment policies, reasonable
periods of illness or other incapacities permitted by the Company’s general
employment policies, and as otherwise provided herein) to the business of the
Company.

          1.2 Ms. Schramke shall serve in a managerial capacity and shall perform such
duties as are customarily associated with her then current title.

          1.3 The employment relationship between the parties is “at will,” which
means that either party may terminate the relationship at any time, with or
without cause and with or without advance notice. The employment relationship
between the parties shall also be governed by the general employment policies
and practices of the Company, including those relating to protection of
confidential information and assignment of inventions, except that when the
terms of this Agreement differ from or are in conflict with the Company’s
general employment policies or practices, this Agreement shall control.

     2. COMPENSATION.

          2.1 Salary. Ms. Schramke shall receive for services to be rendered
hereunder an annualized base salary of One Hundred Eighty-Five Thousand U.S.
Dollars ($185,000), payable on the Company’s normal payroll schedule, and
subject to standard payroll deductions and withholdings.

1.

 

          2.2 Stock Option. Subject to approval by the Board, the Company will
grant Ms. Schramke a nonstatutory stock option (the “Option”) to purchase Seven
Thousand (7,000) shares of the common stock of the Company (the “Common Stock”)
pursuant to the Company’s 1992 Stock Option Plan (the “Plan”), as amended. The
exercise price per share of the Option will be the Fair Market Value (as
defined in the Plan) per share of the Common Stock on the date of grant.
Except as otherwise provided herein, the Option will vest and become
exercisable over five (5) years, with Twenty Percent (20%) of the shares
covered by the Option vesting and becoming exercisable on the first year
anniversary of the date of grant and the remaining Eighty Percent (80%) of the
shares covered by the Option vesting and becoming exercisable in Forty-Eight
(48) equal monthly installments thereafter, in accordance with the Company’s
standard vesting and exercisability policy, as long as Ms. Schramke remains in
continuous service with the Company. The Option will be subject to the terms
of the Plan and Ms. Schramke’s corresponding Stock Option Grant Notice and
Stock Option Agreement.

          2.3 Transaction Bonus. For the period beginning on the Effective Date of
this Agreement and ending on December 31, 2003 (the “Transaction Bonus
Period”), Ms. Schramke shall be eligible to participate in the Business
Development Bonus Plan, attached hereto as Exhibit A.

          2.4 Standard Company Benefits. Ms. Schramke shall be entitled to all
rights and benefits for which she is eligible under the terms and conditions of
the standard Company benefits and compensation practices which may be in effect
from time to time and provided by the Company to its employees generally,
including but not limited to health benefit plans. Ms. Schramke also shall be
eligible to participate in the Company’s 401(k) Plan, including eligibility for
a monthly matching contribution by the Company on Ms. Schramke’s behalf, in an
amount equal to that contributed by Ms. Schramke up to a maximum annual
matching contribution of Seven Hundred Fifty Dollars ($750). Ms. Schramke
shall be provided specific information concerning these Company benefits upon
commencement of her employment.

     3. PROPRIETARY INFORMATION OBLIGATIONS.

          3.1 Agreement. Ms. Schramke agrees to execute and abide by the Employee
Proprietary Information and Inventions Agreement attached hereto as Exhibit B.

          3.2 Remedies. Ms. Schramke’s duties under the Employee Proprietary
Information and Inventions Agreement shall survive termination of her
employment with the Company. Ms. Schramke acknowledges that a remedy at law
for any breach or threatened breach by her of the provisions of the Employee
Proprietary Information and Inventions Agreement would be inadequate, and she
therefore agrees that the Company shall be entitled to injunctive relief in
case of any such breach or threatened breach.

     4. OUTSIDE ACTIVITIES.

          4.1 Except with the prior written consent of the President and Chief
Executive Officer, Ms. Schramke will not during the term of this Agreement
undertake or engage in any other employment, occupation or business enterprise,
other than ones in which Ms. Schramke is a passive investor. Ms. Schramke may
engage in civic and not-for-profit activities so long as such activities do not
materially interfere with the performance of her duties hereunder.

2.

 

          4.2 Except as permitted by Section 4.3, Ms. Schramke agrees not to
acquire, assume or participate in, directly or indirectly, any position,
investment or interest known by her to be adverse or antagonistic to the
Company, its business or prospects, financial or otherwise.

          4.3 During the term of her employment by the Company, except on behalf of
the Company, Ms. Schramke will not directly or indirectly, whether as an
officer, director, stockholder, partner, proprietor, associate, representative,
consultant, or in any capacity whatsoever engage in, become financially
interested in, be employed by or have any business connection with any other
person, corporation, firm, partnership or other entity whatsoever which were
known by her to compete directly with the Company, throughout the world, in any
line of business engaged in (or planned to be engaged in) by the Company;
provided, however, that anything above to the contrary notwithstanding, she may
own, as a passive investor, securities of any competitor corporation, so long
as her direct holdings in any one such corporation shall not in the aggregate
constitute more than One Percent (1%) of the voting stock of such corporation.

     5. TERMINATION
OF EMPLOYMENT.

          5.1 Termination Without Cause.

               (a) The Company shall have the right to terminate Ms. Schramke’s
employment with the Company at any time without cause or advance notice.

               (b) In the event Ms. Schramke’s employment is terminated without Cause (as
defined in section 5.2) by the Company, or by any successor or acquiring entity
upon or after an Asset Sale, Merger, Consolidation, or Reverse Merger (as
defined in the Lynx Therapeutics, Inc. 1992 Stock Option Plan, as amended), Ms.
Schramke shall be eligible to receive severance compensation, calculated as
specified herein, provided that, Ms. Schramke executes a general release of any
and all claims she may have against the Company, which general release shall be
in a form acceptable to the Company. The amount of severance compensation that
Ms. Schramke shall receive shall be calculated pursuant to the following
schedule: (a) if the termination occurs on or prior to the first year
anniversary of Ms. Schramke’s hire date, she shall receive an amount equal to
three (3) months of her base salary, subject to standard payroll deductions and
withholdings, and paid in a lump sum; (b) if the termination occurs after the
first year anniversary of Ms. Schramke’s hire date, she shall receive an amount
equal to at least one (1) month of her base salary, subject to standard payroll
deductions and withholdings, and paid in a lump sum. (“Severance”). The
Severance shall be the only severance, benefit, or cash compensation, other
than accrued wages, to which Ms. Schramke shall be entitled from the Company in
the event of a termination without Cause. In the event, however, that a
successor or acquiring entity is obligated to pay Severance to Ms. Schramke,
such Severance shall be in addition to any equity compensation or benefits for
which Ms. Schramke may be eligible under the Lynx Therapeutics, Inc. 1992 Stock
Option Plan, as amended.

          5.2 Termination for Cause.

               (a) The Company shall have the right to terminate Ms. Schramke’s
employment with the Company at any time for Cause.

               (b) “Cause” for termination shall mean: (a) indictment or conviction of
any felony or of any crime involving dishonesty; (b) participation in any fraud
or act of dishonesty against the Company; (c) Ms. Schramke’s failure to perform
her duties to the Company in a satisfactory

3.

 

manner; (d) intentional damage to any property of the Company; or (e)
conduct by Ms. Schramke which in the good faith and reasonable determination of
the President and Chief Executive Officer demonstrates lack of fitness to
serve.

               (c) In the event Ms. Schramke’s employment is terminated at any time for
Cause, Ms. Schramke will not be entitled to Severance or any other compensation
or benefit other than accrued wages.

          5.3 Voluntary or Mutual Termination.

               (a) Ms. Schramke may voluntarily terminate her employment with the Company at
any time, after which no further compensation will be paid to Ms. Schramke.

               (b) In the event Ms. Schramke voluntarily terminates her employment, she
will not be entitled to Severance or any other such compensation or benefit,
other than accrued wages.

     6. NONINTERFERENCE.

          While employed by the Company, and for two (2) years immediately following
the termination of her employment, Ms. Schramke agrees not to interfere with
the business of the Company by soliciting, attempting to solicit, inducing, or
otherwise causing any employee of the Company to terminate her or her
employment in order to become an employee, consultant or independent contractor
to or for any competitor of the Company.

     7. COOPERATION WITH COMPANY.

          7.1 Cooperation Obligation. During and after Ms. Schramke’s employment,
Ms. Schramke will cooperate with the Company in responding to the reasonable
requests of the Company’s Chairman of the Board, Chief Executive Officer or
General Counsel, in connection with any and all existing or future litigation,
arbitrations, mediations or investigations brought by or against the Company or
its affiliates, agents, officers, directors or employees, whether
administrative, civil or criminal in nature, in which the Company reasonably
deems Ms. Schramke’s cooperation necessary or desirable. In such matters, Ms.
Schramke agrees to provide the Company with reasonable advice, assistance and
information, including offering and explaining evidence, providing sworn
statements, and participating in discovery and trial preparation and testimony.
Ms. Schramke also agrees to promptly send the Company copies of all
correspondence (for example, but not limited to, subpoenas) received by Ms.
Schramke in connection with any such legal proceedings, unless Ms. Schramke is
expressly prohibited by law from so doing. The failure by Ms. Schramke to
cooperate fully with the Company in accordance with this Section 7 will be a
material breach of the terms of this Agreement which will result in all
commitments of the Company to pay Severance to Ms. Schramke under Section 5.1
(b) becoming null and void.

          7.2 Expenses and Fees. The Company will reimburse Ms. Schramke for
reasonable out-of-pocket expenses incurred by Ms. Schramke as a result of her
cooperation with the obligations described in Section 7.1, within thirty (30)
days of the presentation of appropriate documentation thereof, in accordance
with the Company’s standard reimbursement policies and procedures. After
termination of Ms. Schramke’s employment, the Company will also pay Ms.
Schramke a reasonable fee in the amount of $200 per hour for the time Ms.
Schramke devotes to matters as requested by the Company under Section 7.1 (“the
Fees”). The Company will not deduct or withhold any amount from

4.

 

the Fees for taxes, social security, or other payroll deductions, but will
instead issue an IRS Form 1099 with respect to the Fees. Ms. Schramke
acknowledges that in cooperating in the manner described in Section 7.1, she
will be serving as an independent contractor, not a Company employee, and she
will be entirely responsible for the payment of all income taxes and any other
taxes due and owing as a result of the payment of Fees. Ms. Schramke hereby
indemnifies the Company and its officers, directors, agents, attorneys,
employees, shareholders, subsidiaries, and affiliates and holds them harmless
from any liability for any taxes, penalties, and interest that may be assessed
by any taxing authority with respect to the Fees, with the exception of the
employer’s share of employment taxes subsequently determined to be applicable,
if any.

     8. GENERAL PROVISIONS.

          8.1 Notices. Any notices provided hereunder must be in writing and shall
be deemed effective upon the earlier of personal delivery (including personal
delivery by facsimile) or the third day after mailing by first class mail, to
the Company at its primary office location and to Ms. Schramke at her address
as listed on the Company payroll.

          8.2 Severability. Whenever possible, each provision of this Agreement
will be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be invalid,
illegal or unenforceable in any respect under any applicable law or rule in any
jurisdiction, such invalidity, illegality or unenforceability will not affect
any other provision or any other jurisdiction, but this Agreement will be
reformed, construed and enforced in such jurisdiction in order to most closely
effectuate the parties’ intentions.

          8.3 Waiver. If either party should waive any breach of any provisions of
this Agreement, she or it shall not thereby be deemed to have waived any
preceding or succeeding breach of the same or any other provision of this
Agreement.

          8.4 Complete Agreement. This Agreement and its Exhibits constitute the
entire agreement between Ms. Schramke and the Company and it is the complete,
final, and exclusive embodiment of their agreement with regard to this subject
matter. It is entered into without reliance on any promise or representation
other than those expressly contained herein, and it cannot be modified or
amended except in writing signed by a member of the Company’s Board.

          8.5 Counterparts. This Agreement may be executed in separate
counterparts, any one of which need not contain signatures of more than one
party, but all of which taken together will constitute one and the same
Agreement.

          8.6 Headings. The headings of the sections hereof are inserted for
convenience only and shall not be deemed to constitute a part hereof nor to
affect the meaning thereof.

          8.7 Successors and Assigns. This Agreement is intended to bind and inure
to the benefit of and be enforceable by Ms. Schramke and the Company, and their
respective successors, assigns, heirs, executors and administrators, except
that Ms. Schramke may not assign any of her duties hereunder and she may not
assign any of her rights hereunder without the written consent of the Company,
which shall not be withheld unreasonably.

5.

 

          8.8 Attorney’s Fees. If either party hereto brings any action to enforce
her or its rights hereunder, the prevailing party in any such action shall be
entitled to recover her or its reasonable attorneys’ fees and costs incurred in
connection with such action.

          8.9 Governing Law. All questions concerning the construction, validity
and interpretation of this Agreement will be governed by the law of the State
of California. Ms. Schramke hereby expressly consents to the personal
jurisdiction of the state and federal courts located in Alameda County,
California for any lawsuit filed there against Ms. Schramke by the Company
arising from or related to this Agreement.

          IN
WITNESS WHEREOF, the parties have executed this Agreement on the day
and year written below.

	 	 	 	 	 
	 	 	LYNX THERAPEUTICS, INC.
	 
	 	 	 	 
	

	 	By:
	 	/s/ Kathy A. San Roman
	

	 	 	 	

	

	 	 	 	Kathy A. San Roman
	

	 	 	 	Vice President, Human Resources & Administration
	 
	 	 	 	 
	

	 	Date:
	 	January 29, 2003
	 
	 	 	 	 
	Accepted and agreed this
31st day of January 2003.
	 	 	 	 
	 
	 	 	 	 
	/s/ Mary L. Schramke

	 	 	 	February 18, 2003
	

	 	 	 	

	Mary L. Schramke, Ph.D., MBA

	 	 	 	Start Date          

6.

 

EXHIBIT A

BUSINESS DEVELOPMENT BONUS PLAN

1. OBJECTIVE

To develop and implement a Business Development Bonus Plan (“Bonus Plan”)
designed to motivate the Business Development employees, enhance teamwork and
reward effective efforts in achieving individual and team contributions as they
relate to meeting the Company’s revenue and cash flow objectives.

2. EFFECTIVE DATE AND SCOPE OF COVERAGE

This Bonus Plan covers the period of April 1, 2003 to December 31, 2003 (the
“Transaction Bonus Period”). It represents the entire agreement between you and
the Company on this subject, and supersedes all prior bonus compensation
programs or other bonus or commissions arrangements of the Company and all
other previous oral or written statements or agreements to you regarding any
bonus or commissions.

3. ELIGIBILITY

Business Development employees are eligible to participate in the Bonus Plan
only if they are designated as an eligible employee in writing, signed by a
Company officer. All eligible employees must sign the Bonus Plan to participate
in the Bonus Plan. The Company reserves the right to transfer or remove a
participant from the Plan at any time and for any reason, upon written notice
to the participant.

4. QUALIFYING TRANSACTIONS; EARNED TRANSACTION BONUSES

During the Transaction Bonus Period, the participants in the Bonus Plan shall
be eligible to receive a cash bonus equal to a certain percentage (identified
below) of revenue-based customer payments received and recorded by the Company
from any transactions between unaffiliated third parties and the Company (a
“Transaction”) that are identified, initiated and completed by the Business
Development group during the Transaction Bonus Period (the “Transaction
Bonus”). Transaction Bonuses, if any, shall be paid within thirty (30) calendar
days after the Company records receipt of the customer payments. The Company
will determine, in its sole discretion, when and if customer payments are
received and recorded. Participants must be employed as a Business Development
employee in good standing at the time that the customer payment is received and
recorded by the Company to earn the related Transaction Bonus. Transaction
Bonuses earned but not yet paid upon termination of employment or removal from
the Bonus Plan will be paid on the normal Transaction Bonus payment schedule.
No other Transaction Bonuses will be paid following termination of employment
or removal from the Bonus Plan. Transaction Bonuses are subject to standard
payroll deductions and withholdings.

The Company reserves the right to accept and reject customers,
contracts or orders. No Transaction Bonuses will be paid for any
rejected customers, contracts or orders.

5. BONUS CALCULATION

Each participant’s Transaction Bonus amount will be equal to either a Lead or
Group percentage of the customer payments received and recorded by the Company
from Transactions during the Transaction Bonus Period. The Lead percentage is
equal to 0.50% of the received and recorded customer payments, and applies to
the participant if the participant was the lead or primary person who
identified, initiated and completed the Transaction (the “Lead”). The Group
percentage is equal to 0.25% of the received and recorded customer payments,
and applies to

 

 

BUSINESS DEVELOPMENT BONUS PLAN

participants who do not qualify as the Lead. Only one participant can qualify
as the Lead on any single Transaction. The Company’s Vice President of Business
Development will determine, in his or her sole discretion, which participant
qualifies as the Lead. As Sr. Director of Business Development, your percentage
is equal to 0.50% of received and recorded customers payments.

6. PLAN ADMINISTRATION AND INTERPRETATION ; TERMINATION OF PLAN

The Vice President of Business Development will administer and interpret the
Bonus Plan. The Company reserves the right to change, suspend or terminate the
Bonus Plan at any time and for any reason, upon written notice to the
participants. Any changes to or termination of the Bonus Plan must be in
writing signed by a duly authorized officer of the Company.

7. BONUS DISPUTES

A Bonus Review Board will be established to review and decide any disputes
arising under this Bonus Plan that are not resolved by the Vice President of
Business Development. The Bonus Review Board shall consist of the Company’s
Chief Executive Officer, Chief Financial Officer, and Vice President of Human
Resources. Any participant with an issue related to the Bonus Plan that is not
resolved by the Vice President of Business Development shall provide a written
request for review to the Vice President of Human Resources, who shall convene
the Bonus Review Board to resolve the issue. All decisions of the Bonus Review
Board are final and binding.

8. AT-WILL EMPLOYMENT

Nothing in this Bonus Plan is intended to alter the at-will nature of your
employment, i.e., your right or the Company’s right to terminate your
employment at will, at any time with or without cause or advance notice.

ACKNOWLEDGEMENT AND ACCEPTANCE

I have read and understood the provisions of this Bonus Plan and hereby accept its terms.

	 	 	 
	

	 	

	Signature

	 	Date
	 
	 	 
	

	 	 
	Print Name
	 	 

 

 

EXHIBIT B

Lynx Therapeutics, Inc.

EMPLOYEE PROPRIETARY INFORMATION

AND INVENTIONS AGREEMENT

     In consideration of my employment or continued employment by Lynx Therapeutics,
Inc. (the
“Company”), and the compensation now and hereafter paid to me, I hereby agree
as follows:

1. NONDISCLOSURE

     1.1 Recognition of Company’s Rights;
Nondisclosure. At all times during my employment
and thereafter, I will hold in strictest confidence and
will not disclose, use, lecture upon or publish any of
the Company’s Proprietary Information (defined
below), except as such disclosure, use or publication
may be required in connection with my work for the
Company, or unless an officer of the Company
expressly authorizes such in writing. I will obtain
Company’s written approval before publishing or
submitting for publication any material (written,
verbal, or otherwise) that relates to my work at
Company and/or incorporates any Proprietary
Information. I hereby assign to the Company any
rights I may have or acquire in such Proprietary
Information and recognize that all Proprietary
Information shall be the sole property of the Company
and its assigns.

     1.2 Proprietary Information. The
term “Proprietary Information” shall mean any and
all confidential and/or proprietary knowledge, data or
information of the Company. By way of illustration
but not limitation, “Proprietary Information”
includes tangible and intangible information relating
to antibodies and other biological materials, cell lines,
samples of assay components, media and/or cell lines
and procedures and formulations for producing any
such assay components, media and/or cell lines,
formulations, products, processes, know-how,
designs, formulas, methods, developmental or
experimental work, clinical data, improvements,
discoveries, plans for research, new products,
marketing and selling, business plans, budgets and
unpublished financial statements, licenses, prices and
costs, suppliers and customers, and information
regarding the skills and compensation of other
employees of the Company. Notwithstanding the
foregoing, it is understood that, at all such times, I am
free to use information which is generally known in
the trade or industry, which is not gained as result of a
breach of this Agreement, and my own skill,
knowledge, know-how and experience to whatever
extent and in whichever way I wish.

     1.3 Third Party Information. I
understand, in addition, that the Company has
received and in the future will receive from third
parties confidential or proprietary information
(“Third Party Information”) subject to a duty on the
Company’s part to maintain the confidentiality of such
information and to use it only for certain limited
purposes. During the term of my employment and
thereafter, I will hold Third Party Information in the
strictest confidence and will not disclose to anyone
(other than Company personnel who need to know
such information in connection with their work for the
Company) or use, except in connection with my work
for the Company, Third Party Information unless
expressly authorized by an officer of the Company in
writing.

     1.4 No Improper Use of Information
of Prior Employers and Others. During my
employment by the Company I will not improperly
use or disclose any confidential information or trade
secrets, if any, of any former employer or any other
person to whom I have an obligation of
confidentiality, and I will not bring onto the premises
of the Company any unpublished documents or any
property belonging to any former employer or any
other person to whom I have an obligation of
confidentiality unless consented to in writing by that
former employer or person. I will use in the
performance of my duties only information which is
generally known and used by persons with training
and experience comparable to my own, which is
common knowledge in the industry or otherwise
legally in the public domain, or which is otherwise
provided or developed by the Company.

2. ASSIGNMENT OF INVENTIONS.

     2.1 Proprietary Rights. The term
“Proprietary Rights” shall mean all trade secret,
patent, copyright, mask work and other intellectual
property rights throughout the world.

     2.2 Prior Inventions. Inventions, if
any, patented or unpatented, which I made prior to the
commencement of my employment with the Company
are excluded from the scope of this Agreement. To

 

 

preclude any possible uncertainty, I have set forth on
Exhibit B (Previous Inventions) attached hereto a
complete list of all Inventions that I have, alone or
jointly with others, conceived, developed or reduced
to practice or caused to be conceived, developed or
reduced to practice prior to the commencement of my
employment with the Company, that I consider to be
my property or the property of third parties and that I
wish to have excluded from the scope of this
Agreement (collectively referred to as “Prior
Inventions”). If disclosure of any such Prior
Invention would cause me to violate any prior
confidentiality agreement, I understand that I am not
to list such Prior Inventions in Exhibit B but am only
to disclose a cursory name for each such invention, a
listing of the party(ies) to whom it belongs and the
fact that full disclosure as to such inventions has not
been made for that reason. A space is provided on
Exhibit B for such purpose. If no such disclosure is
attached, I represent that there are no Prior Inventions.
If, in the course of my employment with the
Company, I incorporate a Prior Invention into a
Company product, process or machine, the Company
is hereby granted and shall have a nonexclusive,
royalty-free, irrevocable, perpetual, worldwide license
(with rights to sublicense through multiple tiers of
sublicensees) to make, have made, modify, use and
sell such Prior Invention. Notwithstanding the
foregoing, I agree that I will not incorporate, or permit
to be incorporated, Prior Inventions in any Company
Inventions without the Company’s prior written
consent.

     2.3 Assignment of Inventions. Subject
to Sections 2.4, and 2.6, I hereby assign and agree to
assign in the future (when any such Inventions or
Proprietary Rights are first reduced to practice or first
fixed in a tangible medium, as applicable) to the
Company all my right, title and interest in and to any
and all Inventions (and all Proprietary Rights with
respect thereto) whether or not patentable or
registrable under copyright or similar statutes, made
or conceived or reduced to practice or learned by me,
either alone or jointly with others, during the period of
my employment with the Company. Inventions
assigned to the Company, or to a third party as
directed by the Company pursuant to this Section 2,
are hereinafter referred to as “Company Inventions.”

     2.4 Nonassignable Inventions. This
Agreement does not apply to an Invention which
qualifies fully as a nonassignable Invention under
Section 2870 of the California Labor Code
(hereinafter “Section 2870”). I have reviewed the
notification on Exhibit A (Limited Exclusion
Notification) and agree that my signature
acknowledges receipt of the notification.

     2.5 Obligation to Keep Company
Informed. During the period of my employment and
for six (6) months after termination of my
employment with the Company, I will promptly
disclose to the Company fully and in writing all
Inventions authored, conceived or reduced to practice
by me, either alone or jointly with others. In addition,
I will promptly disclose to the Company all patent
applications filed by me or on my behalf within a year
after termination of employment. At the time of each
such disclosure, I will advise the Company in writing
of any Inventions that I believe fully qualify for
protection under Section 2870; and I will at that time
provide to the Company in writing all evidence
necessary to substantiate that belief. The Company
will keep in confidence and will not use for any
purpose or disclose to third parties without my
consent any confidential information disclosed in
writing to the Company pursuant to this Agreement
relating to Inventions that qualify fully for protection
under the provisions of Section 2870. I will preserve
the confidentiality of any Invention that does not fully
qualify for protection under Section 2870.

     2.6 Government or Third Party. I
also agree to assign all my right, title and interest in
and to any particular Company Invention to a third
party, including without limitation the United States,
as directed by the Company.

     2.7 Works for Hire. I acknowledge
that all original works of authorship which are made
by me (solely or jointly with others) within the scope
of my employment and which are protectable by
copyright are “works made for hire,” pursuant to
United States Copyright Act (17 U.S.C., Section 101).

     2.8 Enforcement of Proprietary
Rights. I will assist the Company in every proper
way to obtain, and from time to time enforce, United
States and foreign Proprietary Rights relating to
Company Inventions in any and all countries. To that
end I will execute, verify and deliver such documents
and perform such other acts (including appearances as
a witness) as the Company may reasonably request for
use in applying for, obtaining, perfecting, evidencing,
sustaining and enforcing such Proprietary Rights and
the assignment thereof. In addition, I will execute,
verify and deliver assignments of such Proprietary
Rights to the Company or its designee. My obligation
to assist the Company with respect to Proprietary
Rights relating to such Company Inventions in any
and all countries shall continue beyond the

 

 

termination of my employment, but the Company
shall compensate me at a reasonable rate after my
termination for the time actually spent by me at the
Company’s request on such assistance.

In the event the Company is unable for any reason,
after reasonable effort, to secure my signature on any
document needed in connection with the actions
specified in the preceding paragraph, I hereby
irrevocably designate and appoint the Company and
its duly authorized officers and agents as my agent
and attorney in fact, which appointment is coupled
with an interest, to act for and in my behalf to execute,
verify and file any such documents and to do all other
lawfully permitted acts to further the purposes of the
preceding paragraph with the same legal force and
effect as if executed by me. I hereby waive and
quitclaim to the Company any and all claims, of any
nature whatsoever, which I now or may hereafter have
for infringement of any Proprietary Rights assigned
hereunder to the Company.

3. RECORDS. I agree to keep and maintain
adequate and current records (in the form of notes,
sketches, drawings and in any other form that may be
required by the Company) of all Proprietary
Information developed by me and all Inventions made
by me during the period of my employment at the
Company, which records shall be available to and
remain the sole property of the Company at all times.

4. ADDITIONAL ACTIVITIES. I agree that
during the period of my employment by the Company
I will not, without the Company’s express written
consent, engage in any employment or business
activity which is competitive with, or would otherwise
conflict with, my employment by the Company. I
agree further that for the period of my employment by
the Company and for one (l) year after the date of
termination of my employment by the Company I will
not, either directly or through others, solicit or attempt
to solicit any employee, independent contractor or
consultant of the company to terminate his or her
relationship with the Company in order to become an
employee, consultant or independent contractor to or
for any other person or entity.

5. NO CONFLICTING OBLIGATION. I represent
that my performance of all the terms of this
Agreement and as an employee of the Company does
not and will not breach any agreement to keep in
confidence information acquired by me in confidence
or in trust prior to my employment by the Company. I
have not entered into, and I agree I will not enter into,
any agreement either written or oral in conflict
herewith.

6. RETURN OF COMPANY DOCUMENTS. When
I leave the employ of the Company, I will deliver to
the Company any and all drawings, notes,
memoranda, specifications, devices, formulas, and
documents, together with all copies thereof, and any
other material containing or disclosing any Company
Inventions, Third Party Information or Proprietary
Information of the Company. I further agree that any
property situated on the Company’s premises and
owned by the Company, including disks and other
storage media, filing cabinets or other work areas, is
subject to inspection by Company personnel at any
time with or without notice. Prior to leaving, I will
cooperate with the Company in completing and
signing the Company’s termination statement.

7. LEGAL AND EQUITABLE REMEDIES.
Because my services are personal and unique and
because I may have access to and become acquainted
with the Proprietary Information of the Company, the
Company shall have the right to enforce this
Agreement and any of its provisions by injunction,
specific performance or other equitable relief, without
bond and without prejudice to any other rights and
remedies that the Company may have for a breach of
this Agreement.

8. NOTICES. Any notices required or permitted
hereunder shall be given to the appropriate party at the
address specified below or at such other address as the
party shall specify in writing. Such notice shall be
deemed given upon personal delivery to the
appropriate address or if sent by certified or registered
mail, three (3) days after the date of mailing.

9. NOTIFICATION OF NEW EMPLOYER. In the
event that I leave the employ of the Company, I
hereby consent to the notification of my new
employer of my rights and obligations under this
Agreement.

10. GENERAL PROVISIONS.

     10.1 Governing Law; Consent to
Personal Jurisdiction. This Agreement will be
governed by and construed according to the laws of
the State of California, as such laws are applied to
agreements entered into and to be performed entirely
within California between California residents. I
hereby expressly consent to the personal jurisdiction
of the state and federal courts located in Alameda
County, California for any lawsuit filed there against
me by Company arising from or related to this
Agreement.

 

 

     10.2 Severability. In case any one or
more of the provisions contained in this Agreement
shall, for any reason, be held to be invalid, illegal or
unenforceable in any respect, such invalidity,
illegality or unenforceability shall not affect the other
provisions of this Agreement, and this Agreement
shall be construed as if such invalid, illegal or
unenforceable provision had never been contained
herein. If moreover, any one or more of the
provisions contained in this Agreement shall for any
reason be held to be excessively broad as to duration,
geographical scope, activity or subject, it shall be
construed by limiting and reducing it, so as to be
enforceable to the extent compatible with the
applicable law as it shall then appear.

     10.3 Successors and Assigns. This
Agreement will be binding upon my heirs, executors,
administrators and other legal representatives and will
be for the benefit of the Company, its successors, and
its assigns.

     10.4 Survival. The provisions of this
Agreement shall survive the termination of my
employment and the assignment of this Agreement by
the Company to any successor in interest or other
assignee.

     10.5 Employment. I agree and
understand that nothing in this Agreement shall confer
any right with respect to continuation of employment
by the Company, nor shall it interfere in any way with
my right or the Company’s right to terminate my
employment at any time, with or without cause.

     10.6 Waiver. No waiver by the
Company of any breach of this Agreement shall be a
waiver of any preceding or succeeding breach. No
waiver by the Company of any right under this
Agreement shall be construed as a waiver of any other
right. The Company shall not be required to give
notice to enforce strict adherence to all terms of this
Agreement.

     10.7 Entire Agreement. The obligations
pursuant to Sections 1 and 2 of this Agreement shall
apply to any time during which I was previously
employed, or am in the future employed, by the
Company as a consultant if no other agreement
governs nondisclosure and assignment of inventions
during such period. This Agreement is the final,
complete and exclusive agreement of the parties with
respect to the subject matter hereof and supersedes
and merges all prior discussions between us. No
modification of or amendment to this Agreement, nor
any waiver of any rights under this Agreement, will be
effective unless in writing and signed by the party to
be charged. Any subsequent change or changes in my
duties, salary or compensation will not affect the
validity or scope of this Agreement.

     This Agreement shall be effective as of the
first day of my employment with the Company,
namely: February 18, 2003.

     I HAVE READ THIS AGREEMENT CAREFULLY
AND UNDERSTAND ITS TERMS. I HAVE COMPLETELY
FILLED OUT EXHIBIT B TO THIS AGREEMENT.

	 
	Dated: 2/18/03

	 

	/s/ Mary L. Schramke

	

	(Signature)

	 

	Mary L. Schramke

	

	(Printed Name)

	 

	ACCEPTED AND AGREED TO:

	 

	LYNX THERAPEUTICS, INC.

	 	 	 
	By:

	 	/s/ Cristina Alves
	

	 	

	Title:
	 	HR Coordinator

	 
	25861 Industrial Blvd

	

	(Address)

	 

	Hayward, CA 94545

	 

	Dated: 2/18/03

 

 

EXHIBIT A

LIMITED EXCLUSION NOTIFICATION

     THIS IS TO NOTIFY you in accordance with Section 2872 of the California Labor
Code that the foregoing
Agreement between you and the Company does not require you to assign or offer
to assign to the Company any
invention that you developed entirely on your own time without using the
Company’s equipment, supplies, facilities
or trade secret information except for those inventions that either:

     1. Relate at the time of conception or reduction to practice of the invention
to the Company’s
business, or actual or demonstrably anticipated research or development of the
Company; or

     2. Result from any work performed by you for the Company.

     To the extent a provision in the foregoing Agreement purports to require you to
assign an invention
otherwise excluded from the preceding paragraph, the provision is against the
public policy of this state and is
unenforceable.

     This limited exclusion does not apply to any patent or invention covered by a
contract between the
Company and the United States or any of its agencies requiring full title to
such patent or invention to be in the
United States.

     I ACKNOWLEDGE RECEIPT of a copy of this notification.

	 	 	 	 	 
	

	 	By:
	 	Mary L. Schramke
	

	 	 	 	

	

	 	 	 	(PRINTED NAME OF EMPLOYEE)
	 
	 	 	 	 
	

	 	Date:	 	 2/19/03
	WITNESSED BY:
	 	 	 	 
	 
	 	 	 	 
	Cristina Alves
	 	 	 	 
	

	 	 	 	 
	(PRINTED NAME OF REPRESENTATIVE)
	 	 	 	 
	 
	 	 	 	 
	Lynx
Therapeutics, Inc. 
	 	 	 	Effective Date: 11/01/01
	Employee
Handbook
	 	 	 	 

 

 

EXHIBIT B

TO: Lynx Therapeutics, Inc.

FROM: Mary L. Schramke

DATE: 2/19/03

SUBJECT: Previous Inventions

1. Except as listed in Section 2 below, the following is a complete list of all
inventions or improvements
relevant to the subject matter of my employment by Lynx Therapeutics, Inc. (the
“Company”) that have been made
or conceived or first reduced to practice by me alone or jointly with others
prior to my engagement by the
Company:

	 	 	 	 	 
	

	 	x
	 	No inventions or improvements.
	 
	 	 	 	 
	

	 	o
	 	See below:
	 
	 	 	 	 
	

	 	 	 	

	 
	 	 	 	 
	

	 	 	 	

	 
	 	 	 	 
	

	 	 	 	

o Additional sheets attached.

     2. Due to a prior confidentiality agreement, I cannot complete the disclosure
under Section 1 above with
respect to inventions or improvements generally listed below, the proprietary
rights and duty of confidentiality with
respect to which I owe to the following party(ies):

	 	 	 	 	 	 	 
	

	 	Invention or Improvement
	 	Party(ies)
	 	Relationship
	1.

	 	

	 	

	 	

	 
	 	 	 	 	 	 
	2.

	 	

	 	

	 	

	 
	 	 	 	 	 	 
	3.

	 	

	 	

	 	

o Additional sheets attached.

	 	 	 	 	 
	Lynx
Therapeutics, Inc. 
	 	 	 	Effective Date: 11/01/01
	Employee
Handbookexv10w1

 

EXHIBIT 10.1

Amendment No. 4 to Fourth Amended and Restated

Receivables Purchase Agreement

and

Reaffirmation of Performance Undertakings

          This Amendment No. 4 to Fourth Amended and Restated Receivables Purchase
Agreement and Reaffirmation of Performance Undertakings (this
“Amendment”) is
entered into as of November 18, 2004, among Dairy Group Receivables, L.P.
(“Dairy I”), Dairy Group Receivables II, L.P. (“Dairy II”), Specialty Group
Receivables, L.P. (“Specialty”), Dean National Brand Group, L.P. (“National
Brand” and together with Dairy I, Dairy II and Specialty, the “Sellers” and
each a “Seller”), each entity signatory hereto as a Financial Institution (each
a “Financial Institution” and
collectively, the “Financial Institutions”), each
entity signatory hereto as a Company (each a “Company” and collectively, the
“Companies”), JPMorgan Chase Bank, National Association (successor by merger to
Bank One, NA (Main Office Chicago)), as Agent (the “Agent”), and Dean Foods
Company, as Provider (“Provider”). Capitalized terms used herein and not
otherwise defined shall have the respective meanings set forth in the Fourth
Amended and Restated Receivables Purchase Agreement, dated as of March 30,
2004, among the Sellers, the Servicers party thereto, the Financial
Institutions, the Companies and the Agent (as amended by Amendment No. 1
thereto, dated as of April 5, 2004, as further amended by Amendment No. 2
thereto, dated as of June 3, 2004, and as further amended by Amendment No. 3
thereto, dated as of August 13, 2004, the “Receivables Purchase Agreement”).

R E C I T A L S:

          The Sellers, the Financial Institutions, the Companies, the Servicers and
the Agent are parties to the Receivables Purchase Agreement.

          In connection with the Receivables Purchase Agreement, Provider entered
into each of (i) that certain Third Amended and Restated Performance
Undertaking, dated as of March 30, 2004, by Provider in favor of Dairy I, (ii)
that certain Second Amended and Restated Performance Undertaking, dated as of
March 30, 2004, by Provider in favor of Dairy II, (iii) that certain Specialty
Performance Undertaking, dated as of November 20, 2003, by Provider in favor of
Specialty and (iv) that certain National Brand Performance Undertaking, dated
as of March 30, 2004, by Provider in favor of National Brand (collectively, the
“Performance Undertakings”).

          The Sellers, Companies, Financial Institutions and the Agent desire
to amend the Receivables Purchase Agreement, and Provider desires to
reaffirm its obligations under the Performance Undertakings, all as more
fully described herein.

 

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED 

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

          NOW, THEREFORE, in consideration of the premises, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto hereby agree as follows:

          Section 1. Amendment. Immediately upon the satisfaction of each of the
conditions precedent set forth in Section 3 of this Amendment, the
Receivables Purchase Agreement is hereby amended as follows:

               (a) Exhibit I to the Receivables Purchase Agreement is hereby amended by
amending and restating, in their entirety, the definitions of “Liquidity
Termination Date”, “Loss Reserve” and “Loss Reserve Percentage” where each such
definition appears therein to read as follows:

     “Liquidity Termination Date” means November 17, 2005.

     “Loss Reserve” means the product of (i) the Net Receivables Balance
and (ii) the greater of (a) the Loss Reserve Percentage and (b) 0.09.

     “Loss Reserve Percentage” means, for any Purchaser Interest on any
date, an amount equal to 2 times the Loss Ratio multiplied by the Loss
Horizon Ratio,

	 	 	 	 	 
	where:
	 	 	 	 
	 
	 	 	 	 
	Loss Ratio

	 	=
	 	As of the last day of any calendar month, the highest
three month rolling average Loss Proxy Ratio in the most
recent twelve months prior to such month.
	 
	 	 	 	 
	Loss Proxy Ratio

	 	=
	 	As of the last day of any calendar month, (x) the sum of
(i) the Outstanding Balance of all Receivables originated
by Loss Proxy Reporting Originators as to which any
payment, or part thereof, remains unpaid for more than 90
but less than 121 days from the original invoice date for
such payment, (ii) the Outstanding Balance

2

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED 

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

	 	 	 	 	 
	

	 	 	 	of all Receivables originated by
Non-Loss Proxy Reporting Originators as to
which any payment, or part thereof,
remains unpaid for more than 90 days
from the original invoice date for such
payment, and (iii) the Outstanding
Balance of all Receivables that have
been written off a Seller’s book as
uncollectible during such month that
were less than 91 days from the
original invoice date, divided by (y)
the aggregate sales for the calendar
month occurring three months
immediately prior to such month.
	 
	 	 	 	 
	Loss Proxy Reporting

	 	 	 	 
	Originators
	 	=
	 	All Originators for which any Monthly
Report lists the Outstanding Balance of
all Receivables of such Originators as
to which any payment, or part thereof,
remains unpaid for more than 90 but
less than 121 days from the original
invoice date for such payment.
	 
	 	 	 	 
	Loss Horizon Ratio

	 	=
	 	As of the last day of any calendar
month, (x) the aggregate amount of
sales for all of the Originators for the
two calendar months most recently
ended, divided by (y) the Net
Receivables Balance as of such day.
	 
	 	 	 	 
	Non-Loss Proxy Reporting
	 	 	 	 
	Originators

	 	=
	 	All Originators other than the Loss
Proxy Reporting Originators.

               (b) Exhibit I to the Receivables Purchase Agreement is
hereby
amended by amending and restating the definition of the term “MRA” where such
term is defined in the definition of “Dilution Reserve” in its entirety to read
as follows:

3

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED 

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

	 	 	 	 	 
	MRA

	 	=
	 	0.03 at any time when the Servicers shall have failed to deliver a
consolidating Monthly Report pursuant to Section 8.5 that is in form
and substance satisfactory to the Agent in its sole discretion and at
all other times and at any time when the Agent in its sole discretion,
shall otherwise determine, 0.00.

          Section 2. Reaffirmation of Performance Guaranty. Provider acknowledges
the amendments to the Receivables Purchase Agreement effected hereby and
reaffirms that its obligations under each of the Performance Undertakings and
each other Transaction Document to which it is a party continue in full force
and effect with respect to the Receivables Purchase Agreement.

          Section 3. Conditions to Effectiveness of Amendment. This Amendment shall
become effective as of the date hereof upon the satisfaction of the following
conditions precedent:

               (a) Amendment. This Amendment shall have been duly executed
and delivered by each of the parties hereto.

               (b) Representations and Warranties. As of the date hereof, both
before and after giving effect to this Amendment, all of the
representations and warranties
contained in the Receivables Purchase Agreement and in each other
Transaction Document
shall be true and correct as though made on and as of the date hereof (and
by its execution
hereof, each Seller shall be deemed to have represented and warranted
such).

               (c) No Amortization Event or Potential Amortization Event. As of
the date hereof, both before and after giving effect to this Amendment, no
Amortization
Event or Potential Amortization Event shall have occurred and be
continuing (and by its execution hereof, each Seller shall be deemed to have represented and
warranted such).

               (d) Amendment Fees. Each of the Purchasers shall have received a
non-refundable, fully-earned amendment fee equal to $25,000 in immediately
available funds; provided that with respect to the Purchaser for which JPMorgan
Chase Bank, National Association (successor by merger to Bank One, NA (Main Office
Chicago)) is the Financial Institution, such fee shall have been received by J.P. Morgan
Securities, Inc.

          Section 4. Miscellaneous.

4

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED 

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

               (a) Effect; Ratification. The amendments set forth herein
are
effective solely for the purposes set forth herein and shall be limited
precisely as written, and shall not be deemed to (i) be a consent to any
amendment, waiver or modification of any other term or condition of the
Receivables Purchase Agreement or of any other instrument or agreement referred
to therein; or (ii) prejudice any right or remedy which the Companies, the
Financial Institutions or the Agent may now have or may have in the future
under or in connection with the Receivables Purchase Agreement or any other
instrument or agreement referred to therein. Each reference in the Receivables
Purchase Agreement to “this Agreement,” “herein,” “hereof and words of like
import and each reference in the other Transaction Documents to the
“Receivables Purchase Agreement” or to the “Purchase Agreement” or to the
Receivables Purchase Agreement shall mean the Receivables Purchase Agreement as
amended hereby. This Amendment shall be construed in connection with and as
part of the Receivables Purchase Agreement and all terms, conditions,
representations, warranties, covenants and agreements set forth in the
Receivables Purchase Agreement and each other instrument or agreement referred
to therein, except as herein amended, are hereby ratified and confirmed and
shall remain in
full force and effect.

               (b) Transaction Documents. This Amendment is a Transaction
Document executed pursuant to the Receivables Purchase Agreement and shall
be construed, administered and applied in accordance with the terms and
provisions thereof.

               (c) Costs, Fees and Expenses. Each Seller agrees to reimburse the
Agent and the Purchasers upon demand for all costs, fees and expenses
(including the reasonable fees and expenses of counsels to the Agent and the Purchasers)
incurred in connection with the preparation, execution and delivery of this Amendment

               (d) Counterparts. This Amendment may be executed in any number
of counterparts, each such counterpart constituting an original and all of
which when taken
together shall constitute one and the same instrument.

               (e) Severability. Any provision contained in this Amendment which
is held to be inoperative, unenforceable or invalid in any jurisdiction
shall, as to that
jurisdiction, be inoperative, unenforceable or invalid without affecting
the remaining provisions of this Amendment in that jurisdiction or the operation,
enforceability or validity of such provision in any other jurisdiction.

5

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED 

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

               (f) GOVERNING LAW. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED
AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF ILLINOIS.

(Signature Pages Follow)

6

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

     IN WITNESS WHEREOF, the parties hereto have executed this
Amendment as of the date first written above.

DAIRY GROUP RECEIVABLES, L.P.,
 as a
Seller

By: Dairy Group Receivables GP, LLC,

Its: General Partner

DAIRY GROUP RECEIVABLES II, L.P.,
 as a
Seller

By: Dairy Group Receivables GP II, LLC,

Its: General Partner

SPECIALTY GROUP RECEIVABLES, L.P.,
 as a
Seller

By: Specialty
Group Receivables GP, LLC,

Its: General Partner

DEAN NATIONAL BRAND GROUP, L.P.,
 as a
Seller

By: Dean National Brand Group GP, LLC,

Its: General Partner

	 	 	 
	By:

	 	/s/ Cory M. Olson

	

	 	

	Name: Cory M. Olson

	Title: Senior Vice President

 

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

FALCON ASSET SECURITIZATION 

CORPORATION, as a Company

	 	 	 
	By:

	 	/s/ Sherri Gerner

	

	 	

	Name: Sherri Gerner

	Title: Authorized Signer

JPMORGAN CHASE BANK,

NATIONAL ASSOCIATION (successor by merger to BANK ONE,

NA (MAIN OFFICE CHICAGO)),

as a Financial Institution and as Agent

	 	 	 
	By:

	 	/s/ Sherri Gerner

	

	 	

	Name: Sherri Gerner

	Title: Vice President

 

     AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

ATLANTIC ASSET SECURITIZATION CORP.,

as a Company

	 	 	 
	By:

	 	Calyon New York Branch (successor
to Credit
Lyonnais New York Branch)
	 
	Its:

	 	Attorney-In-Fact

	 	 	 
	By:

	 	/s/ David C. Fink
	

	 	

	Name: David C. Fink

	Title: Managing Director
	 
	 	 
	By:

	 	/s/ Anthony Brown
	

	 	

	Name: ANTHONY BROWN

	Title: VICE PRESIDENT

CALYON NEW. YORK BRANCH (successor to Credit

Lyonnais New York Branch), as a
Financial Institution

	 	 	 
	By:

	 	/s/ David C. Fink
	

	 	

	Name: David C. Fink

	Title: Managing Director
	 
	 	 
	By:

	 	/s/ Anthony Brown
	

	 	

	Name: ANTHONY BROWN

	Title: VICE PRESIDENT

 

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

NIEUW AMSTERDAM RECEIVABLES

CORPORATION,

as a Company

	 	 	 
	By:

	 	/s/ Tony Wong

	

	 	

	Name: Tony Wong

	Title: Vice President

COOPERATIEVE CENTRALE RAIFFEISEN

BOERENLEENBANK B.A. “Rabobank International”,

New York Branch,

as a Financial Institution

	 	 	 
	By:
	 	 
	

	 	

	Name:

	Title:
	 
	 	 
	By:
	

	 	

	Name:
	Title:

 

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

NIEUW AMSTERDAM RECEIVABLES

CORPORATION,

as a Company

	 	 	 
	By:
	 	 
	

	 	
 
	Name:
	 	 
	Title:
	 	 

COOPERATIEVE CENTRALE RAIFFEISEN

BOERENLEENBANK B.A. “Rabobank International”,

New York Branch,

as a Financial Institution

	 	 	 
	By:

	 	/s/ Brett Delfino
	

	 	
 
	Name:

	 	Brett Delfino
	Title:

	 	Executive Director

	 	 	 
	By:

	 	/s/ Michael Halevi
	

	 	
 
	Name:

	 	MICHAEL HALEVI
	Title:

	 	Vice President

 

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

BLUE RIDGE ASSET FUNDING CORPORATION,

as a Company

	 	 	 
	By:

	 	Wachovia Capital Markets, LLC
	Its:

	 	Attorney-In-Fact

	 	 	 
	By:

	 	/s/ Douglas R. Wilson, Sr.
	

	 	
 
	Name:

	 	DOUGLAS R. WILSON, SR.
	Title:

	 	VICE PRESIDENT

WACHOVIA BANK, NATIONAL ASSOCIATION,

as a Financial Institution

	 	 	 
	By:
	 	 
	

	 	
 
	Name:
	 	 
	Title:
	 	 

 

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

BLUE RIDGE ASSET FUNDING CORPORATION,

as a Company

By: Wachovia Capital Markets, LLC

Its: Attorney-In-Fact

	 	 	 	 	 
	By:

	 	 	 	 
	

	 	
 	 	 
	Name:
	 	 
	Title:
	 	 

WACHOVIA BANK, NATIONAL ASSOCIATION,

as a Financial Institution

	 	 	 	 	 
	By:

	 	/s/ Rodney Sanders
	 	 
	

	 	
 	 	 
	Name: Rodney Sanders	 	 
	Title: Director	 	 

 

 

AMENDMENT NO. 4 TO FOURTH AMENDED AND RESTATED

RECEIVABLES PURCHASE AGREEMENT AND REAFFIRMATION

OF PERFORMANCE UNDERTAKINGS

DEAN FOODS COMPANY,

as Provider

	 	 	 	 	 
	By:

	 	/s/ Cory M. Olson
	 	 
	

	 	
 	 	 
	Name: Cory M. Olson	 	 
	Title: Senior Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]